Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06675123 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06675123 · ClinicalTrials.gov record · last posted 2026-08-05

Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma

StatusRecruiting
PhasePhase 1
Started2026-10-01
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This phase I trial tests the safety and side effects of pacritinib in combination with a Bruton's tyrosine kinase (BTK) inhibitor and how well it works in treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Pacritinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. BTK inhibitors block a protein called BTK which is present on B-cell (a type of white blood cell) cancers such as mantle cell lymphoma at abnormal levels. This may help keep tumor cells from growing and spreading. Giving pacritinib in combination with a BTK inhibitor may be safe, tolerable and/or effective in treating patients with relapsed or refractory mantle cell lymphoma.

Amendment record 3 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 3 times since 2024-11-04; most recent amendment 2026-04-01. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2025-09-08
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT06675123
Lead Sponsor City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)
Conditions Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Enrollment 10 participants
Start Date 2026-10-01
Primary Completion 2028-03-08 (estimated)
Study Completion 2028-03-08 (estimated)
Updated on ClinicalTrials.gov 2026-08-05